Kazia Therapeutics Reports 100% Clinical Benefit Rate In Initial Six Patients Treated For Advanced Triple-Negative Breast Cancer
KZIA•Study timeline
Kazia Therapeutics said phase 1b study enrollment is expected to complete by July 2027, with interim clinical updates anticipated throughout 2026 and 2027.
Initial phase 1b results
Aug. 27 (Reuters) - Kazia Therapeutics Ltd. reported a 100% clinical benefit rate in the initial six patients treated for advanced triple-negative breast cancer.
The company also reported an 83% objective response rate in the six patients.
Safety and biomarker findings
Kazia Therapeutics said all patients showed a median 83% reduction in CTC clusters and 51% in exhausted T cells.
No treatment-related serious adverse events were observed.
